It is controversial whether stem cell transplantation (SCT) or chemotherapy is preferable in the treatment of patients with hematologic malignancies. In general, SCT results in fewer relapses but more treatment-related deaths than chemotherapy. Some Japanese hematologists are speculating that the outcome of SCT is better in Japanese recipients compared with Caucasian because Japanese recipients undergoing SCT may have a lower frequency of treatmentrelated mortality. Morishima et al 1, 2 reported the low incidence of acute GVHD following HLA-identical or unrelated donor transplantation among Japanese recipients. However, the incidence of hepatic veno-occlusive disease (VOD), another life-threatening complication of stem cell transplantation, in Japan is unknown. To examine the incidence of VOD after SCT in Japan, we retrospectively investigated 1634 patients who underwent transplantation in 23 transplantation centers participating in Cancer Research Project (No. 7-3) of the Ministry of Health and Welfare, Japan, for the period from 1991 to 1995. The diagnosis of VOD was based on the criteria of McDonald. 3 Among the 1634 patients, 435 were excluded because of an incomplete description on the clinical findings of VOD. Of 1199 evaluable patients, 69 (5.8%) met our clinical criteria for the diagnosis of VOD including 32 with mild VOD, 18 with moderate VOD and 19 with severe VOD. Most of the patients received busulfan (Bu) (16 mg/kg) and cyclophosphamide (CY) (120 mg/kg) or CY (120 mg/kg) and total body irradiation (12 Gy) as conditioning therapy. The relationship between VOD and the type of transplant was examined by comparing the frequency of VOD among allogeneic vs autologous graft recipients, and among allogeneic recipients who received HLA-matched, -mismatched, and unrelated donor hematopoietic cells, respectively. VOD developed in 41 of 683 patients (6.0%) who received hematopoietic cells from an HLA-identical sibling, eight of 44 (18.2%) who received hematopoietic cells from HLA-mismatched siblings or other relatives, 14 of 214 (6.5) who received cells from unrelated donors, and six of 259 (2.3%) who received autologous hematopoietic cells. The incidence of VOD in patients who received allogeneic transplants was significantly higher than among patients who received autologous transplants (P = 0.004). Patients who were transplanted from an HLA-identical sibling had less VOD than patients who were transplanted from an HLAmismatched siblings or other relatives (P = 0.002). However, there was no significant difference in the incidence of VOD among patients who received hematopoietic cells from HLA-identical siblings vs patients who received cells from unrelated donors (P = 0.919).
VOD occurs in 1-54% of SCT. 4 Incidence of VOD may be influenced by the toxicity of conditioning regimens, patient selection, and the diagnostic criteria for VOD. However, the incidence of VOD in Japanese HLA-identical sibling transplant recipients in this survey was similar to the incidence reported by the IBMTR, 5 but significantly lower than that reported from Seattle. 6 The likely explanations for this disparity are first, the regimens of cytoreductive therapy used in Seattle are more intensive than those in use in Japan and Europe, and second, our retrospective diagnosis of VOD probably missed the milder cases of VOD. It is of interest that the incidence of VOD in recipients transplanted from unrelated donors was as low as that among HLA-identical sibling transplant recipients, but the reason is unknown.
In conclusion, the incidence of VOD in Japanese recipients of stem cell transplants appears to be similar to that of European, Caucasian recipients receiving similar doses of cytoreductive therapy. VOD remains a cause of transplant-related morbidity and mortality after stem cell transplantation in Japanese recipients. The paper by EB Papadopoulos and colleagues 1 adds support to our earlier observations published some 5 years ago. 2 However, the American programme differs in three significant ways.
Firstly, there is marked contrast in the complexity of the two approaches. Specifically, their technique for T cell depletion involves exposure of the bone marrow to sequential soybean lectin agglutination and sheep red blood rosette depletion. In contrast, the Constantiaberg Medi-Clinic method is simplicity itself, where 20 mg of CAMPATH 1G was added to the bag in vitro, gently agitated at room temperature for 30 min, and everything infused without further manipulation.
Secondly, the New York group emphasised that rejection prophylaxis and graft-versus-host disease are risk factors in their hands. Therefore, they add antithymocyte globulin and methylprednisolone in anticipation of graft failure. Since we have not seen this complication no such intervention is needed and the patients are spared significant additional costs and potential side-effects. Thirdly, with 20 AML patients transplanted with marrow as the source of haematopoietic stem cells and the longest follow-up of 8 years with a median of 5 years, neither acute nor chronic graft-versus-host disease (GVHD) has been seen. Similarly, cytomegaloviral infection was absent from our original experience, 2 but occurred in one graft at 3 months when prophylaxis was discontinued, and the patient died from pneumonitis. Since the first report, four individuals have relapsed: two died at 3 months, one at a year and one at 7 years. Two others, one transplanted in relapse and one who developed disseminated varicella zoster, have died. The remaining patients are well and continue in complete remission.
In the last 4 years this programme has been modified by using mononuclear cells recovered from the peripheral blood (PBSC) by apheresis technology. 3 Furthermore, the rat monoclonal CAMPATH 1G (n = 11: median follow-up 20 months) has been discontinued and substituted with the humanised version 1H (n = 33: median follow-up 9 months). 4 Accepting that numbers are small and followup short, these 44 patients, transplanted with a variety of haematologic disorders, have been characterized by uniform engraftment after the standardised preparative programme. 3 There has been a striking reduction in time to achieve corresponding peripheral blood count values. Thus, for 0.5 and 1.0 × 10 9 /l circulating granulocytes the values after marrow infusion were 18 (9-34) and 28 (10-59) days and for platelets of 25 and 50 × 10 9 /l, 17 (5-32) and 27 (13-127) days. In contrast, the corresponding figures for disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
peripheral blood being 12 (12-40) and platelets 12 (12-42) and (12-51) days. This reduction of approximately 1 week markedly reduces costs for hospitalization, need for nephrotoxic antibiotics and transfusion of blood and platelets.
In the combined group (n = 44) there were eight patients with AML and, to date, none have relapsed. Among those whose PBSC were exposed to the now discontinued CAMPATH 1G, none developed CMV, while two had mild erythroderma.
With CAMPATH 1H, four have sero-converted to CMV and another four had a skin rash. Biopsy has failed to reveal any evidence of classic GVHD. Whether this is grade I cutaneous manifestation which is a forme frust due to the T cell depletion, as opposed to being virus or drug-related, is unproven.
The most notable observation parallels that of Dr Papadopoulos and associates in which the earlier experience, reported with marrow as the source of the graft, has a low relapse rate in patients with AML. Although it is too early to be sure of what will happen with peripheral blood stem cells a similar pattern appears to be emerging. Whilst commenting here primarily on acute myelogenous leukaemia, similarly excellent results have been obtained with idiopathic bone marrow failure, Fanconi anaemia, lymphomas, chronic myeloid leukaemia, and a small number of solid tumours. As originally pointed out, 2 we believe our data are consistent with GVHD not being an obligatory correlate with a separate graft-versus-leukaemia benefit that is associated with allogeneic haematopoietic stem and progenitor cell transplantation. It is our viewpoint that CAMPATH 1G, or preferably 1H, is an alternative to the American programme, and perhaps a rather simpler approach to achieving acceptably similar results.
These ongoing investigations, which are part of the larger activity of the Campath Users Group, 4 are shortly to be formally updated (Hale, unpublished), but we would take the stance that marrow no longer needs to be used, since an equally effective and considerably less expensive source of the required lymphohaematopoietic population can be derived from the peripheral blood using cell separator technology. Furthermore, we do not believe that it is justifiable to continue using unmodified marrow allografts, given the benefits that are evident from ex vivo manipulation, resulting in uniform engraftment, absence of acute and chronic graft-versus-host disease, and a surprisingly low incidence of viral infection and an acceptable leukaemic relapse rate in AML. Our current activities centre on documenting the patterns of immunologic reconstitution, since manipulation of total cell numbers and mononuclear subtype in the infused graft, as well as biologic immune response modulation, may further reduce erythroderma and post-transplant infectious episodes. This model using matched siblings is the basis for extending the identical practice to matched unrelated volunteer donor grafts.
